2,5-Dimethoxy-4-methyl-amphetamine (STP): A New Hallucinogenic Drug
Solomon H. Snyder, Louis A. Faillace, Leo E. Hollister
Science November 3, 1967 DOI: 10.1126/science.158.3801.669 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Population | Normal control volunteers |
| Interventions | 2 5-Dimethoxy-4-methyl-amphetamine |
| Dose | greater than 3 milligrams |
| Duration | About 8 hours |
| Topics | LSD Mescaline Psilocybin |
| Keywords | Hallucinogen Euphoriant Pharmacology Dextroamphetamine |
| Citations | 146 |
| Key findings | 2,5-Dimethoxy-4-methyl-amphetamine produces mild euphoria at low doses and pronounced hallucinogenic effects at doses above 3 milligrams, with potency between mescaline and lysergic acid diethylamide. |
Abstract
We have assessed the effects in normal control volunteers of 2,5-dimethoxy-4-methyl-amphetamine, the chemical present in the hallucinogenic drug STP, in two independent trials. In low doses, this compound produces a mild euphoria. Doses greater than 3 milligrams may cause pronounced hallucinogenic effects lasting about 8 hours and similar to those produced by hallucinogenic doses of lysergic acid diethylamide, mescaline, and psilocybin. 2,5-Dimethoxy-4-methyl-amphetamine, which is chemically related to mescaline and amphetamine, is about 100 times more potent as a hallucinogen than mescaline and only one-thirtieth as potent as lysergic acid diethylamide. Its psychological effects are not accentuated by chlorpromazine.
Comparable studies
Other observational and cohort studies on mescaline, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psychedelics not linked to mental health problems or suicidal behavior: A population study Randomly selected United States adults | 2015 | Observational cohort | n = 135,095 |
| Long-lasting subjective effects of LSD in normal subjects Healthy participants | 2017 | Observational cohort | n = 16 |
| Psychological and cognitive effects of long-term peyote use among Native Americans. Navajo Native Americans aged 18-45 | 2005 | Observational cohort | n = 176 |
| Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research. Normal men who were volunteers | 1992 | Observational cohort | n = 12 |
| EFFECTS OF MESCALINE AND LYSERGIC ACID (d-LSD-25) Schizophrenic patients and normal individuals | 1952 | Observational study |
Citations in the library
Cited by 43
- 3,4‐Methylenedioxymethamphetamine (MDMA, “Ecstasy”): pharmacology and toxicology in animals and humans Addiction May 1, 1994
- Stereochemical effects of 3,4-methylenedioxymethamphetamine (MDMA) and related amphetamine derivatives on inhibition of uptake of [3H]monoamines into synaptosomes from different regions of rat brain. Biochemical Pharmacology July 15, 1987
- Dreams, Hallucinogenic Drug States, and Schizophrenia: A Psychological and Biological Comparison Schizophrenia Bulletin 1983
- Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens. Current Topics in Behavioral Neurosciences 2017
- Hallucinogenic Drugs in Psychiatric Research and Treatment Perspectives and Prospects The Journal of Nervous and Mental Disease March 1, 1995
and 38 more in the library